Targeting Coagulase Activity in Staphylococcus aureus Bacteraemia: A Randomized Controlled Single-Centre Trial of Staphylothrombin Inhibition

Marijke Peetermans; Laurens Liesenborghs; Kathelijne Peerlinck; Eric Van Wijngaerden; Olivier Gheysens; Karolien E. Goffin; Marc F. Hoylaerts; Marc Jacquemin; Jan Verhaegen; Willy E. Peetermans; Peter Verhamme; Thomas Vanassche; for the Staphylothrombin Investigators

doi:10.1055/s-0038-1639586

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2018; 118(05): 818-829
DOI: 10.1055/s-0038-1639586

Coagulation and Fibrinolysis

Schattauer GmbH Stuttgart

Targeting Coagulase Activity in Staphylococcus aureus Bacteraemia: A Randomized Controlled Single-Centre Trial of Staphylothrombin Inhibition

Marijke Peetermans

¹Center for Molecular and Vascular Biology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium

²Department of Internal Medicine, University Hospitals Leuven, Leuven, Belgium

,

Laurens Liesenborghs

¹Center for Molecular and Vascular Biology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium

²Department of Internal Medicine, University Hospitals Leuven, Leuven, Belgium

,

Kathelijne Peerlinck

¹Center for Molecular and Vascular Biology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium

³Department of Cardiovascular Sciences, University Hospitals Leuven, Leuven, Belgium

,

Eric Van Wijngaerden

²Department of Internal Medicine, University Hospitals Leuven, Leuven, Belgium

⁴Department of Immunology and Microbiology, University of Leuven, Leuven, Belgium

,

Olivier Gheysens

⁵Nuclear Medicine and Molecular Imaging, University Hospitals Leuven, Leuven, Belgium

,

Karolien E. Goffin

⁵Nuclear Medicine and Molecular Imaging, University Hospitals Leuven, Leuven, Belgium

,

Marc F. Hoylaerts

¹Center for Molecular and Vascular Biology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium

,

Marc Jacquemin

¹Center for Molecular and Vascular Biology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium

⁶Department of Haemostasis in Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium

,

Jan Verhaegen

⁷Department of Clinical Bacteriology and Mycology, University Hospitals Leuven, Leuven, Belgium

,

Willy E. Peetermans

²Department of Internal Medicine, University Hospitals Leuven, Leuven, Belgium

⁴Department of Immunology and Microbiology, University of Leuven, Leuven, Belgium

,

Peter Verhamme

¹Center for Molecular and Vascular Biology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium

³Department of Cardiovascular Sciences, University Hospitals Leuven, Leuven, Belgium

,

Thomas Vanassche

¹Center for Molecular and Vascular Biology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium

³Department of Cardiovascular Sciences, University Hospitals Leuven, Leuven, Belgium

,

for the Staphylothrombin Investigators

› Author Affiliations

Abstract

Background Staphylococcus aureus (S. aureus) bacteraemia is frequent and carries a high morbidity and mortality. Coagulases secreted by S. aureus initiate blood coagulation by directly activating prothrombin. This pathogen-activated coagulation is insensitive to most antithrombotic drugs, with the exception of small molecule direct thrombin inhibitors (DTIs). DTIs inhibit the coagulase-prothrombin complex, or staphylothrombin, and improve outcome in preclinical models of S. aureus infection.

Objective A single-centre, randomized, controlled feasibility and safety trial of staphylothrombin inhibition with DTIs in patients with S. aureus bacteraemia.

Patients and Methods Consecutive eligible adult patients with S. aureus positive blood cultures in the University Hospitals Leuven (Belgium) were randomized 1:1 to DTI (oral dabigatran 110 mg twice daily or intravenous argatroban according to activated partial thromboplastin time [aPTT]) for 7 to 10 days, or subcutaneous enoxaparin 40 mg once daily. Primary outcomes were feasibility and safety of DTI in patients with S. aureus bacteraemia. Secondary outcomes include D-dimer evolution (day 0–4) as marker of coagulation activation; inflammatory and microbiological parameters; and clinical outcomes including metastatic infections.

Results Thirty-one percent (94/303) of screened patients were enrolled. Dabigatran plasma levels inhibited staphylothrombin. Clinically relevant bleeding (5/47 vs. 5/47) and thrombotic (7/47 vs. 7/47) complications were similar in both groups. Coagulase inhibition with DTIs was associated with a trend towards faster D-dimer decrease at day 4 (–662 ± 249 ng/mL vs. –40 ± 213 ng/mL for DTI-treated patients vs. control; p = 0.06) and a numerically lower number of persistently positive blood cultures. No differences in inflammatory parameters or other clinical outcomes were observed.

Conclusion Targeting staphylothrombin with DTIs is feasible in a subset of S. aureus bacteraemic patients, with comparable safety to standard thromboprophylaxis. In future studies of staphylothrombin inhibition, feasibility can be further improved by rapid diagnostics and by strategies without concomitant anticoagulant effect.

Keywords

anticoagulants - bacteraemia - coagulase - Staphylococcus aureus - thrombin

Full Text

References

References
1 de Kraker ME, Jarlier V, Monen JC, Heuer OE, van de Sande N, Grundmann H. The changing epidemiology of bacteraemias in Europe: trends from the European Antimicrobial Resistance Surveillance System. Clin Microbiol Infect 2013; 19 (09) 860-868
2 Holland TL, Arnold C, Fowler Jr VG. Clinical management of Staphylococcus aureus bacteremia: a review. JAMA 2014; 312 (13) 1330-1341
3 Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler Jr VG. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev 2015; 28 (03) 603-661
4 Kern WV. Management of Staphylococcus aureus bacteremia and endocarditis: progresses and challenges. Curr Opin Infect Dis 2010; 23 (04) 346-358
5 Thwaites GE, Edgeworth JD, Gkrania-Klotsas E. , et al; UK Clinical Infection Research Group. Clinical management of Staphylococcus aureus bacteraemia. Lancet Infect Dis 2011; 11 (03) 208-222
6 Huang J, Qian W, Gan M. A study on antimicrobial resistance of coagulase negative staphylococci [in Chinese]. Zhonghua Nei Ke Za Zhi 1995; 34 (09) 620-622
7 Qian Q, Eichelberger K, Kirby JE. Rapid identification of Staphylococcus aureus in blood cultures by use of the direct tube coagulase test. J Clin Microbiol 2007; 45 (07) 2267-2269
8 Vanassche T, Verhaegen J, Peetermans WE. , et al. Inhibition of staphylothrombin by dabigatran reduces Staphylococcus aureus virulence. J Thromb Haemost 2011; 9 (12) 2436-2446
9 Panizzi P, Nahrendorf M, Figueiredo JL. , et al. In vivo detection of Staphylococcus aureus endocarditis by targeting pathogen-specific prothrombin activation. Nat Med 2011; 17 (09) 1142-1146
10 Peetermans M, Verhamme P, Vanassche T. Coagulase activity by Staphylococcus aureus: a potential target for therapy?. Semin Thromb Hemost 2015; 41 (04) 433-444
11 McAdow M, Kim HK, Dedent AC, Hendrickx AP, Schneewind O, Missiakas DM. Preventing Staphylococcus aureus sepsis through the inhibition of its agglutination in blood. PLoS Pathog 2011; 7 (10) e1002307
12 Vanassche T, Kauskot A, Verhaegen J. , et al. Fibrin formation by staphylothrombin facilitates Staphylococcus aureus-induced platelet aggregation. Thromb Haemost 2012; 107 (06) 1107-1121
13 Vanassche T, Peetermans M, Van Aelst LN. , et al. The role of staphylothrombin-mediated fibrin deposition in catheter-related Staphylococcus aureus infections. J Infect Dis 2013; 208 (01) 92-100
14 Kahn SR, Lim W, Dunn AS. , et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e195S-e226S
15 Soulier JP, Prou-Wartelle O. Study of thrombin-coagulase. Thromb Diath Haemorrh 1967; 17 (3-4): 321-334
16 Vanassche T, Verhaegen J, Peetermans WE, Hoylaerts MF, Verhamme P. Dabigatran inhibits Staphylococcus aureus coagulase activity. J Clin Microbiol 2010; 48 (11) 4248-4250
17 Hijikata-Okunomiya A, Kataoka N. Argatroban inhibits staphylothrombin. J Thromb Haemost 2003; 1 (09) 2060-2061
18 Alatri A, Armstrong AE, Greinacher A. , et al. Results of a consensus meeting on the use of argatroban in patients with heparin-induced thrombocytopenia requiring antithrombotic therapy - a European Perspective. Thromb Res 2012; 129 (04) 426-433
19 Parker MJ, Manan A, Duffett M. Rapid, easy, and cheap randomization: prospective evaluation in a study cohort. Trials 2012; 13: 90
20 Schulman S, Angerås U, Bergqvist D, Eriksson B, Lassen MR, Fisher W. ; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010; 8 (01) 202-204
21 Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012; 23 (02) 138-143
22 Frydman AM, Bara L, Le Roux Y, Woler M, Chauliac F, Samama MM. The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharmacol 1988; 28 (07) 609-618
23 Claes J, Vanassche T, Peetermans M. , et al. Adhesion of Staphylococcus aureus to the vessel wall under flow is mediated by von Willebrand factor-binding protein. Blood 2014; 124 (10) 1669-1676
24 Vos FJ, Bleeker-Rovers CP, Sturm PD. , et al. 18F-FDG PET/CT for detection of metastatic infection in Gram-positive bacteremia. J Nucl Med 2010; 51 (08) 1234-1240
25 Bernard GR, Vincent JL, Laterre PF. , et al; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344 (10) 699-709
26 Desjardins L, Bara L, Boutitie F. , et al. Correlation of plasma coagulation parameters with thromboprophylaxis, patient characteristics, and outcome in the MEDENOX study. Arch Pathol Lab Med 2004; 128 (05) 519-526
27 Reilly PA, Lehr T, Haertter S. , et al; RE-LY Investigators. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 2014; 63 (04) 321-328
28 Chapman GH, Berens C, Peters A, Curcio L. Coagulase and hemolysin tests as measures of the pathogenicity of Staphylococci. J Bacteriol 1934; 28 (04) 343-363
29 Begins K, Church W, Maddur A. , et al. An anti-staphylocoagulase monoclonal antibody inhibits prothrombin activation and prolongs survival in mice following Staphylococcus aureus infection. J Thromb Haemost 2015; 13: 257-258

Supplementary Material

Supplementary Figures